INTERNATIONAL PATENT: IMMATICS BIOTECHNOLOGIES GMBH FILES APPLICATION FOR "NOVEL T CELL RECEPTORS TARGETING MELANOMA-ASSOCIATED ANTIGEN (MAGE) B2 AND IMMUNE THERAPY USING THE SAME"

GENEVA, Feb. 3 -- IMMATICS BIOTECHNOLOGIES GMBH (Paul-Ehrlich-StraBe 1572076 Tubingen) filed a patent application (PCT/EP2024/071264) for "NOVEL T CELL RECEPTORS TARGETING MELANOMA-ASSOCIATED ANTIGEN (MAGE) B2 AND IMMUNE THERAPY USING THE SAME" on Jul 26, 2024. With publication no. WO/2025/021979, the details related to the patent application was published on Jan 30, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): UNVERDORBEN, Felix (Paul-Ehrlich-StraBe 1572076 Tubingen), WAGNER, Claudia (Paul-Ehrlich-StraBe 1572076 Tubingen), MAURER, Dominik (Paul-Ehrlich-StraBe 1572076 Tubingen), YOUSEF, S...